Hall R E, Tilley W D, McPhaul M J, Sutherland R L
Cancer Biology Division, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, NSW, Australia.
Int J Cancer. 1992 Nov 11;52(5):778-84. doi: 10.1002/ijc.2910520518.
Although the androgen receptor (AR) has been detected by ligand-binding assays, there is little known about the expression and regulation of the AR gene in human breast-cancer cells. AR mRNA, measured by Northern analysis in 18 cell lines, was found to be expressed predominantly in oestrogen- and progesterone-receptor-positive (ER+, PR+) lines as a single species of approximately 10.5 kb but was also comparatively abundant in I ER- and PR-negative cell line, MDA-MB-453. Dexamethasone (Dex), Organon 2058 (Org 2058), dihydrotestosterone (DHT), and all-trans-retinoic acid (RA) down-regulated AR mRNA levels in T-47D (ER+, PR+) cells 6 hr after treatment, whereas oestradiol (E2) had no effect. In MDA-MB-453 (ER-, PR-) cells, regulation of AR mRNA by RA differed from the other cell lines: RA increased the level of AR mRNA. DHT-binding assays indicated a corresponding increase in AR protein. Transfection of the androgen-responsive mouse mammary tumour virus long-terminal repeat (MMTV LTR) linked to a chloramphenicol acetyltransferase (CAT) reporter gene was used to examine the effect of altered AR levels on androgen action. The increased level of AR following RA pre-treatment in MDA-MB-453 cells resulted in enhanced induction of CAT activity by DHT and, conversely, a decrease in the level of AR following RA pretreatment in T-47D cells resulted in reduced induction of CAT activity by DHT. These data demonstrate that AR is expressed predominantly in ER+ and PR+ cell lines and its expression is regulated by ligands also known to regulate ER or PR, including progestins and retinoids. Androgen responsiveness measured by a transfected reporter gene was altered according to the extent of up- or down-regulation of AR expression, demonstrating that responsiveness is dependent on receptor concentration.
尽管通过配体结合试验已检测到雄激素受体(AR),但关于AR基因在人乳腺癌细胞中的表达和调控却知之甚少。通过Northern分析在18种细胞系中检测AR mRNA,发现其主要在雌激素和孕激素受体阳性(ER +,PR +)的细胞系中表达,为单一的约10.5 kb的条带,但在一种ER - 和PR - 的细胞系MDA - MB - 453中也相对丰富。地塞米松(Dex)、奥加农2058(Org 2058)、二氢睾酮(DHT)和全反式维甲酸(RA)在处理6小时后下调T - 47D(ER +,PR +)细胞中的AR mRNA水平,而雌二醇(E2)则无影响。在MDA - MB - 453(ER -,PR -)细胞中,RA对AR mRNA的调控与其他细胞系不同:RA增加AR mRNA的水平。DHT结合试验表明AR蛋白相应增加。将与氯霉素乙酰转移酶(CAT)报告基因相连的雄激素反应性小鼠乳腺肿瘤病毒长末端重复序列(MMTV LTR)转染,用于检测AR水平改变对雄激素作用的影响。MDA - MB - 453细胞经RA预处理后AR水平升高,导致DHT对CAT活性的诱导增强,相反,T - 47D细胞经RA预处理后AR水平降低,导致DHT对CAT活性的诱导减弱。这些数据表明,AR主要在ER +和PR +细胞系中表达,其表达受已知可调节ER或PR的配体调控,包括孕激素和类维生素A。通过转染报告基因测定的雄激素反应性根据AR表达上调或下调的程度而改变,表明反应性取决于受体浓度。